Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. - Wikidata - wikimedia - TriplyDB

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

http://www.wikidata.org/entity/Q34714310

about

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Molecular Targeted Therapies of Aggressive Thyroid Cancer Internal radiation therapy: a neglected aspect of nuclear medicine in the molecular era Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib Sorafenib in metastatic thyroid cancer: a systematic review Cabozantinib for progressive metastatic medullary thyroid cancer: a review Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Progress in molecular-based management of differentiated thyroid cancer Medical management of metastatic medullary thyroid cancer Current status and future perspectives in differentiated thyroid cancer Sunitinib: the antiangiogenic effects and beyond Recent Updates on the Management of Medullary Thyroid Carcinoma Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Evolving Therapies and FAK Inhibitors for the Treatment of Cancer 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.Update: the status of clinical trials with kinase inhibitors in thyroid cancer Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma.Comparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG uptake in lymph node metastasis of differentiated thyroid cancer.A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.Update on thyroid cancer treatment.Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.Multikinase inhibitors use in differentiated thyroid carcinoma.Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial Activated RET and ROS: two new driver mutations in lung adenocarcinoma.Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.New therapies for dedifferentiated papillary thyroid cancer Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report.Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

P2860

Q26751274-38162F07-A909-48E5-86EF-FCB5696C279A Q26764899-58463DA5-07C7-4402-B2E5-AE9DDD99B7AC Q26774734-EF231DFE-0086-460E-A1B7-585C23F4E427 Q26786554-12BBD528-8A13-4054-A4D5-31AA977E18FC Q26821959-71AF35A7-092E-4CAE-A423-62920221F851 Q26828884-8DE200F1-09BD-406B-B404-63BBE3B570C0 Q26851709-012E3302-8D1B-4ADC-BB9C-7C0986E0321B Q26862841-C9A35309-5EA3-422C-B477-FDB6FA8FD2EC Q26863326-E2133CAF-7DDF-4D86-B933-4892518A6E95 Q26999887-F577F9F2-08D8-4528-A523-238FEA520B7E Q27005897-3AE068B8-9834-4B5F-AA8E-5527FD33A1B9 Q27024484-6B3203CE-A9C2-4F1C-B975-1160F853726D Q28066499-4C5D4F5F-DF47-479F-B74A-1AC6980E03BA Q28066911-B37083D3-4A8B-4E62-A88D-764EAEF3FF0B Q28072655-5A230733-FBA0-40C3-9DFB-61D867C4C6F5 Q28972291-1F28244B-1A91-4515-848C-636159787179 Q30367068-765B133F-E2EB-4F87-8772-6FDD5948AD31 Q33405318-8124E61D-467D-4058-9B67-5E1B80D3E51A Q33569049-2536F87B-E792-4AC6-A811-7EAE32088DC0 Q33570056-81B34943-7026-4F92-B180-D9397B0F4DC5 Q33632654-8CB4B9F4-D8F4-46D9-A4C1-D308C918A556 Q33633431-7538375E-1271-4089-8C69-B9D3D5B10E4A Q33682381-63D427D6-4644-4132-8115-52790A827447 Q33687963-CD4CCF24-F7EF-42D8-BB9C-2D3CE9C9FD92 Q33793550-9B401905-1E03-41ED-A612-DB64F245B3B8 Q33852864-535A4638-1906-4F35-BFAA-9CDFBE98B4EA Q34131012-B4332F3D-50C0-4631-A323-4386CE4967CF Q34310219-BFF40917-ADB9-47CA-84FA-A7823AA52AB9 Q34318833-0735E9A3-3B97-4378-AE8D-72914FADAC84 Q34538390-ED024804-B465-498A-9E5F-991F58FB3648 Q34660901-D4937E11-02C7-469D-85F0-63E9F19F97C9 Q35038893-99C84D60-C638-4421-A36E-A738B0A80C8D Q35057314-31B3D1A2-BC7D-4DAE-A559-A34BAF59E464 Q35195766-BA2B97A8-EECF-4E14-92F1-781B77AAAD1D Q35206630-B001DAB9-C542-4443-90E1-4DF23C6DEDF0 Q35295368-A378BB2E-0278-4F79-B97F-D40D0E897EB9 Q35381593-BCC45A5A-2691-42FA-9677-8C0EA8880260 Q35396089-99E6DF6C-DEA5-4CA8-B0D0-6E128CCEE291 Q35803876-90636D6F-F43D-45FA-A4BF-686BEE170EC2 Q35864072-6F6C1B0F-BF78-49CA-8BD0-E4FFA1DBECDD

P2860

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

http://www.wikidata.org/entity/Q34714310

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II study of daily suniti ...... unctional imaging correlation.

@ast

Phase II study of daily suniti ...... unctional imaging correlation.

@en

Phase II study of daily suniti ...... unctional imaging correlation.

@nl

type

label

Phase II study of daily suniti ...... unctional imaging correlation.

@ast

Phase II study of daily suniti ...... unctional imaging correlation.

@en

Phase II study of daily suniti ...... unctional imaging correlation.

@nl

prefLabel

Phase II study of daily suniti ...... unctional imaging correlation.

@ast

Phase II study of daily suniti ...... unctional imaging correlation.

@en

Phase II study of daily suniti ...... unctional imaging correlation.

@nl

P1433

Q34714310-E15088CA-FB2D-42D5-B339-E9E4F95FAB31

P1476

Q34714310-70A2B9DA-0693-4CB3-92C1-794091BBEA5E

P2093

Q34714310-4B286957-C758-4FFC-9AE6-98C71E61707D

Q34714310-6B195913-9BF3-42F7-A64F-2B58A5CA5A09

Q34714310-883E5D8E-5A60-453D-9E33-2D230503933A

Q34714310-A9DBAC04-B3AD-4FF1-B92A-B7E0F89D18A6

Q34714310-BF0A84D8-1316-497F-813D-A5F732FF78CA

Q34714310-DAB3AC21-1E26-4B0F-BB56-923E8C904C51

Q34714310-E4438105-A8E4-4B61-B5A4-93DFEB068D28

Q34714310-EF4697F3-C440-48D7-B142-A0B144F9F5A2

P2860

Q34714310-119C0160-F32B-4D49-8288-05B81B8B2814

Q34714310-18CCDF33-00F8-47B4-8B14-54A0D6512559

Q34714310-27F55C2E-BBBF-4935-9BDA-B2A7A31D742E

Q34714310-280CBB66-8E72-410E-A893-D80B60EFC408

Q34714310-2966D8BE-DBF8-443B-83EC-4438D6A2D4CA

Q34714310-2B587930-9394-46FC-BF6F-9936355BB265

Q34714310-2F823CE8-B0E9-40C7-8AA1-5084A8FB2926

Q34714310-33C1C5DE-ED0A-41C4-80C4-E3AD80A6FCA3

Q34714310-3A4C8150-467E-4306-838D-CCB1E6D8A9B1

Q34714310-3D200374-F826-4DAE-B55A-E90586836361

P304

Q34714310-C3AE7DF8-CE4C-4C3D-94C8-118D044A1FA6

P31

Q34714310-5565BEDA-170C-48B8-91E0-68794486C4BD

P356

Q34714310-617EC3FA-C59B-4FC4-BCD4-44CDFFB28A05

P407

Q34714310-C3B25C4A-99BE-4947-A161-CC77F5969373

P433

Q34714310-886F7952-585F-46E5-8595-97567C647DDD

P478

Q34714310-097C73A0-F44A-4A02-A7B2-6440D79C67DD

P577

Q34714310-BF590A4F-8922-466A-A12A-094A0ACD0555

P698

Q34714310-FB6A91B2-52E4-457A-AE7C-2618583164CB

P932

Q34714310-A838AE8C-ED15-43D2-86E2-AF698690A9C0

P356

1078-0432.CCR-10-0994

P1433

Clinical Cancer Research

P1476

Phase II study of daily suniti ...... unctional imaging correlation.

@en

P2093

Bernardo H Goulart

http://www.w3.org/2001/XMLSchema#string

David A Mankoff

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Kell

http://www.w3.org/2001/XMLSchema#string

Julie E Bauman

http://www.w3.org/2001/XMLSchema#string

Keith D Eaton

http://www.w3.org/2001/XMLSchema#string

Laurie L Carr

http://www.w3.org/2001/XMLSchema#string

Peter T Capell

http://www.w3.org/2001/XMLSchema#string

Renato G Martins

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

Motesanib diphosphate in progressive differentiated thyroid cancer.

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

New therapeutic approaches for metastatic thyroid carcinoma.

Sunitinib: from rational design to clinical efficacy.

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

P304

5260-5268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0994

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20847059

http://www.w3.org/2001/XMLSchema#string

P932

3063514

http://www.w3.org/2001/XMLSchema#string